Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of Activated T-lymphocyte ("Immuncell-LC") Cell Therapy in Gemcitabine Refractory Advanced Pancreatic Cancer.

Trial Profile

Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of Activated T-lymphocyte ("Immuncell-LC") Cell Therapy in Gemcitabine Refractory Advanced Pancreatic Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Nov 2014

At a glance

  • Drugs T-lymphocyte cell therapy (Primary)
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Jun 2013 New source identified and integrated (ClinicalTrials.gov; NCT00965718).
    • 04 Jul 2011 New trial record
    • 29 Jun 2011 Results from 16 patients were reported at the Spring Conference of the Korean Pancreatobiliary Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top